BioSpace News Archive

RemeGen Co. Ltd., a commercial-stage biotechnology company, with a mission that is closely aligned with the Close the Care Gap theme of World Cancer Day 2024 which falls on February 4, has announced three major developments that will further the global fight against cancer and forge new paths in tumor treatments.

Inmagene Biopharmaceuticals announced that it exercised the option to obtain an exclusive, worldwide and royalty-bearing license for IMG-007, a non-depleting humanized anti-OX40 mAb, and IMG-004, an oral non-covalent and reversible BTK inhibitor, with the right to sublicense through multiple tiers.

Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced that it has received marketing authorization from the Puerto Rico Department of Health for Endari®.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 24 new employees.

ORIC Pharmaceuticals, Inc. announced that on February 1, 2024, ORIC granted a total of 12,500 non-qualified stock options and 2,100 restricted stock units to two new non-executive employees who began their employment with ORIC in January 2024.

Spyre Therapeutics, Inc. announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 125,000 shares of common stock of Spyre to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended.

Zura Bio Limited, a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced that members of its senior management team will participate at several upcoming conferences in February.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 32,100 shares, and restricted stock units (RSUs) covering an aggregate of 21,450 shares, of BioCryst common stock.

Sio Gene Therapies, Inc. (“Sio”) today announced that it expects to file a certificate of dissolution (the “Certificate of Dissolution”) with the Secretary of State of the State of Delaware, as contemplated by the Plan of Complete Liquidation and Dissolution (the “Plan”) previously approved by Sio’s Board of Directors and stockholders, on February 7, 2024.